Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The ROSE Scale-Up Study: Informing a decision about ROSE as universal postpartum depression prevention

Award Number: R01MH130948
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

The ROSE Scale-Up Study: Informing a decision about ROSE as universal postpartum depression prevention - Project Summary/Abstract Postpartum depression (PPD) is a common and impactful public health problem, which can have severe and lasting consequences for the mother and infant, and sometimes the entire family. The Reach Out, Stand Strong, Essentials for New Mothers (ROSE) program is an evidence-based intervention that prevents half of cases of postpartum depression and was one of two interventions recommended by the US Preventive Services Task Force in 2019. All effectiveness trials of ROSE and of the other recommended PPD prevention intervention included only low-income women a single risk factor that doubles incidence of PPD. Thus, the existing evidence base for PPD prevention consists primarily of women at increased risk for PPD. Based on data from the PIs’ current implementation study of ROSE (R01 MH114883), many healthcare and community agencies in this implementation trial (78%) find it is more feasible for them to provide or offer ROSE to every woman as part of their standard work flow (i.e., provide it as universal prevention), than it is to create a screening and referral process for at risk women (i.e., an indicated or selective prevention approach). In addition to being more feasible for agencies, universal prevention may also be advantageous because the cost of a screening false negative (resulting in a preventable case of PPD; $32,000) far exceeds the cost of ROSE delivery ($50-$300/woman). Effectiveness of ROSE among low-income women at risk for PPD is known (ROSE prevents ~50% of PPD cases). To inform a recommendation about using ROSE as universal vs. selective or indicated prevention, we need to determine the effectiveness of ROSE among general populations of women, including women screening negative for PPD risk (defined in various ways). Thus, this project will assess ROSE effectiveness across PPD risk levels and across prevention approaches in a sample of 2,320 women from a large regional health system (based in Detroit, MI). Each proposed aim gathers a piece of information missing that is needed to guide decision-making about ROSE as universal prevention. We will assess ROSE as universal, selective, and indicated prevention in terms of: (1) ROSE effectiveness relative to a control for each prevention approach in preventing PPD and improving functioning; (2) cost-outcome, (3) disparity, and (4) scalability of each prevention approach; and (5) mechanisms of ROSE effects across PPD risk levels. We will integrate results to advise about ROSE as universal prevention. This definitive PPD prevention trial will show how best to get an evidence-based program to those who need it in settings where they receive perinatal care by addressing a pragmatic and novel question (should ROSE be universal prevention?) and by examining effectiveness and cost-outcome of universal vs. other prevention approaches.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,249,953 )
2026	2026	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 360	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	5	6/30/2026	NON-COMPETING CONTINUATION	$1,249,953
														Subtotal = $1,249,953

Issue Date FY: 2025 ( Subtotal = $1,194,067 )
2025	2025	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	4	9/16/2025	NON-COMPETING CONTINUATION	$1,194,067
														Subtotal = $1,194,067

Issue Date FY: 2024 ( Subtotal = $1,228,171 )
2024	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	3	6/28/2024	NON-COMPETING CONTINUATION	$1,228,171
														Subtotal = $1,228,171

Issue Date FY: 2023 ( Subtotal = $1,228,026 )
2023	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	2	8/10/2023	NON-COMPETING CONTINUATION	$1,228,026
														Subtotal = $1,228,026

Issue Date FY: 2022 ( Subtotal = $1,333,743 )
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	000	1	8/8/2022	NEW	$1,333,743
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Mental Health Research Grants	001	1	8/9/2022	NEW	$0
														Subtotal = $1,333,743

Grand Total All Awards = $6,233,960

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The ROSE Scale-Up Study: Informing a decision about ROSE as universal postpartum depression prevention

Award Number: R01MH130948

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer